Effects of Ziclague® (Alpinia zerumbet) in patients with hereditary spastic paraplegia

Phase 3

Recruiting

• Conditions: Spasticity, Ziclague, Hereditary Spastic Paraplegia; C10.500.300.820; C05.651.512

• Registration Number: RBR-83xh37
• Lead Sponsor: niversidade Estadual de Campinas (UNICAMP)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-08-28
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: Not specified

Inclusion Criteria

Age between 18 and 80 years old. Clinical diagnosis of Hereditary Spastic Paraplegia. Ability to walk out of home. Assistive devices are permitted

Exclusion Criteria

Wheelchair bound patients. Additional neurological symptoms that may significantly impact gait such as ataxia, lower motor neuron disease, polyneuropathy, mental retardation or dementia. Fixed tendon contractures. Current botulinum toxin injection or in the last six months. Pregnants or breastfeeding. Refusal to consent form. Skin infection or inflammation at site of interest.

Study & Design

• Study Type: Intervention
• Study Design: Not specified